

# Marta S Martins

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7386459/publications.pdf>

Version: 2024-02-01

29  
papers

1,423  
citations

516215

16  
h-index

500791

28  
g-index

30  
all docs

30  
docs citations

30  
times ranked

2180  
citing authors

#	ARTICLE	IF	CITATIONS
1	Predictive and Therapeutic Implications of a Novel PLC $\beta$ 1/SHP2-Driven Mechanism of Cetuximab Resistance in Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 1203-1216.	3.2	7
2	Broad Spectrum Functional Activity of Structurally Related Monoanionic Au(III) Bis(Dithiolene) Complexes. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7146.	1.8	5
3	HERVs establish a distinct molecular subtype in stage II/III colorectal cancer with poor outcome. <i>Npj Genomic Medicine</i> , 2021, 6, 13.	1.7	17
4	Frequent and Persistent PLCG1 Mutations in S $\alpha$ zary Cells Directly Enhance PLC $\beta$ 1 Activity and Stimulate NF $\kappa$ B, AP-1, and NFAT Signaling. <i>Journal of Investigative Dermatology</i> , 2020, 140, 380-389.e4.	0.3	25
5	On the path to gold: Monoanionic Au bisdithiolate complexes with antimicrobial and antitumor activities. <i>Journal of Inorganic Biochemistry</i> , 2020, 202, 110904.	1.5	17
6	TCox: Correlation-Based Regularization Applied to Colorectal Cancer Survival Data. <i>Biomedicines</i> , 2020, 8, 488.	1.4	4
7	Biological properties of a new mixed lanthanide(III) complex incorporating a dypiridinium ylide. <i>Inorganica Chimica Acta</i> , 2020, 506, 119517.	1.2	8
8	Pt-Fe ferrocenyl compounds with hydroxyquinoline ligands show selective cytotoxicity on highly proliferative cells. <i>Journal of Inorganic Biochemistry</i> , 2019, 199, 110779.	1.5	16
9	Exploring the cytotoxic activity of new phenanthroline salicylaldimine Zn(II) complexes. <i>Journal of Inorganic Biochemistry</i> , 2019, 198, 110727.	1.5	37
10	Alzheimer's disease phospholipase C-gamma-2 (PLCG2) protective variant is a functional hypermorph. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 16.	3.0	100
11	Antitumour and Toxicity Evaluation of a Ru(II)-Cyclopentadienyl Complex in a Prostate Cancer Model by Imaging Tools. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2019, 19, 1262-1275.	0.9	13
12	Novel PLCG2 Mutation in a Patient With APLAID and Cutis Laxa. <i>Frontiers in Immunology</i> , 2018, 9, 2863.	2.2	64
13	Anti-EGFR Therapy to Treat Metastatic Colorectal Cancer: Not for All. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1110, 113-131.	0.8	19
14	Dynamic Allostery in PLC $\beta$ 1 and Its Modulation by a Cancer Mutation Revealed by MD Simulation and NMR. <i>Biophysical Journal</i> , 2018, 115, 31-45.	0.2	10
15	Healthcare professionals approach paediatric fever in significantly different ways and fever phobia is not just limited to parents. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2016, 105, 829-833.	0.7	32
16	Tumor suppressor role of phospholipase C $\mu$ in Ras-triggered cancers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 4239-4244.	3.3	41
17	Activity of PLC $\mu$ contributes to chemotaxis of fibroblasts towards PDGF. <i>Journal of Cell Science</i> , 2012, 125, 5758-5769.	1.2	18
18	Cold Urticaria, Immunodeficiency, and Autoimmunity Related to PLCG2 Deletions. <i>New England Journal of Medicine</i> , 2012, 366, 330-338.	13.9	391

#	ARTICLE	IF	CITATIONS
19	A Hypermorphic Missense Mutation in PLCG2 , Encoding Phospholipase C <sup>3</sup> 2, Causes a Dominantly Inherited Autoinflammatory Disease with Immunodeficiency. American Journal of Human Genetics, 2012, 91, 713-720.	2.6	327
20	Structural and Functional Integration of the PLC <sup>3</sup> Interaction Domains Critical for Regulatory Mechanisms and Signaling Deregulation. Structure, 2012, 20, 2062-2075.	1.6	77
21	Insights into the Phylogeny of Arylamine N-Acetyltransferases in Fungi. Journal of Molecular Evolution, 2010, 71, 141-152.	0.8	23
22	An Acetyltransferase Conferring Tolerance to Toxic Aromatic Amine Chemicals. Journal of Biological Chemistry, 2009, 284, 18726-18733.	1.6	44
23	Human arylamine N-acetyltransferase 1 (NAT1) as a target of chemotherapeutic drugs in breast cancer: cisplatin as a model. Molecular and Cellular Pharmacology, 2009, 1, 7-10.	1.7	2
24	Functional and Structural Characterization of the Arylamine N-Acetyltransferase from the Opportunistic Pathogen Nocardia farcinica. Journal of Molecular Biology, 2008, 383, 549-560.	2.0	26
25	Identification of the Xenobiotic-Metabolizing Enzyme Arylamine N-Acetyltransferase 1 as a New Target of Cisplatin in Breast Cancer Cells: Molecular and Cellular Mechanisms of Inhibition. Molecular Pharmacology, 2008, 73, 1761-1768.	1.0	47
26	The conserved glycine/alanine residue of the active-site loop containing the putative acetylCoA-binding motif is essential for the overall structural integrity of Mesorhizobium loti arylamine N-acetyltransferase 1. Biochemical and Biophysical Research Communications, 2007, 361, 256-262.	1.0	3
27	Cloning and Molecular Characterization of Three ArylamineN-Acetyltransferase Genes from Bacillus anthracis: Identification of Unusual Enzymatic Properties and Their Contribution to Sulfamethoxazole Resistance. Biochemistry, 2007, 46, 7069-7078.	1.2	41
28	Crystallization and preliminary X-ray characterization of arylamine N-acetyltransferase C (BanatC) from Bacillus anthracis. Acta Crystallographica Section F: Structural Biology Communications, 2007, 63, 862-864.	0.7	6
29	Landscape of Current Targeted Therapies for Advanced Colorectal Cancer. , 0, , .		0